A review of chemotherapeutic plaque control.
Of the plaque-control agents studied, it would appear that chlorhexidine is the most suitable agent to prevent plaque accumulation and the development of gingivitis. It also is attractive to speculate on the possibilities of a commercially available mouthwash. A trio of antibiotics--kanamycin, spiramycin, and vancomycin--may prove of value in the treatment of severe gingival and periodontal disease. The ultimate role of xylitol has yet to be determined. Regardless of the agent selected, access to the gingival sulcus region seems critical.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001548:Benzalkonium Compounds / Q000627:therapeutic use; D001645:Biguanides / Q000627:therapeutic use; D002594:Cetylpyridinium / Q000627:therapeutic use; D002710:Chlorhexidine / Q000627:therapeutic use; D003773:Dental Plaque / Q000517:prevention & control*; D003910:Dextranase / Q000627:therapeutic use; D004358:Drug Therapy; D004917:Erythromycin / Q000627:therapeutic use; D005459:Fluorides / Q000627:therapeutic use; D006027:Glycosides / Q000627:therapeutic use; D006801:Humans; D007455:Iodine / Q000627:therapeutic use; D007612:Kanamycin / Q000627:therapeutic use; D007933:Leucomycins / Q000627:therapeutic use; D010194:Pancreatin / Q000627:therapeutic use; D010406:Penicillins / Q000627:therapeutic use; D000644:Quaternary Ammonium Compounds / Q000627:therapeutic use; D013752:Tetracycline / Q000627:therapeutic use; D014640:Vancomycin / Q000627:therapeutic use; D014993:Xylitol / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D001548:Benzalkonium Compounds; D001645:Biguanides; D006027:Glycosides; D007933:Leucomycins; D010406:Penicillins; D000644:Quaternary Ammonium Compounds; D007612:Kanamycin; D004917:Erythromycin; D014640:Vancomycin; D010194:Pancreatin; D007455:Iodine; D002594:Cetylpyridinium; D003910:Dextranase; D013752:Tetracycline; D005459:Fluorides; D002710:Chlorhexidine; D014993:Xylitol